Vision testing in geographic atrophy treated with pegcetacoplan
Part of Eyes & vision clinical trials.
This study tests a specialized vision-testing method in people with geographic atrophy (a type of dry age-related macular degeneration) who are already receiving pegcetacoplan injections. The goal is to better understand how this treatment affects vision in different parts of the eye.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 65–90 years
- Diagnosed with geographic atrophy from dry AMD in at least one eye, with a lesion size between 1–15 mm²
- Already receiving pegcetacoplan injections (at least one before enrolling)
- Vision in the study eye between 20/20 and 20/200 on standard eye charts
- Able to complete specialized vision testing and eye imaging
- No active wet macular degeneration, severe cataracts, or other eye conditions that could interfere with testing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses specialized eye imaging to track changes in geographic atrophy, a type of vision loss from macular degeneration. Researchers will use new imaging techniques to better understand how this condition progresses and how treatments work.
This study observes how geographic atrophy (an advanced form of dry age-related macular degeneration) changes over a short period. If you have this condition in both eyes and meet certain vision and eye health criteria, you may be able to join this non-treatment study to help researchers learn more about the disease.
This study uses special eye imaging to look closely at areas of damage in the back of the eye (geographic atrophy) caused by age-related macular degeneration. It will help doctors understand early-stage disease better and may guide future treatments.
This trial is testing a new eye implant (TO-O-1007) to see if it's safe and helps slow vision loss from geographic atrophy, a late stage of dry age-related macular degeneration (AMD). The implant is placed inside the eye and releases medicine over time.
This study looks at how avacincaptad pegol (brand name Izervay) works in real-world medical practice for people with geographic atrophy, a form of age-related macular degeneration that causes vision loss. If your doctor has already decided to treat you with this medicine, you may be able to join.
This trial tests whether stimulating a nerve in the back of the nose (pterygopalatine ganglion) can slow or improve vision loss from geographic atrophy, a type of age-related macular degeneration. Geographic atrophy causes progressive damage to the central retina, gradually affecting sight.
Hear when a new Geographic Atrophy From Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.